








Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: 
do they justify the switch from ticlopidine to clopidogrel 
after coronary stent placement?
Peter B Berger
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Abstract
In the Ticlid or Plavix Post-Stents (TOPPS) trial, 1016 patients undergoing successful
coronary stent placement were randomized to receive aspirin and either ticlopidine or
clopidogrel. In this trial, the dosages and regimens of ticlopidine and clopidogrel resembled
more closely those used in most catheterization laboratories than did the two previous
randomized trials comparing ticlopidine and clopidogrel. The results of the TOPPS trial
support the current practice of substituting ticlopidine for clopidogrel in stent patients.
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Interventionalists around the world have largely changed
the thienopyridine they use after coronary stent placement
from ticlopidine to clopidogrel. There are several reasons
that this switch has occurred even though five well-
designed randomized trials [1–5] proved that the adminis-
tration of ticlopidine, with aspirin, was superior at reducing
stent thrombosis and other adverse events after coronary
stent placement than aspirin and warfarin, or aspirin alone.
Ticlopidine causes severe neutropenia in more than 1% of
patients in the first few months of ticlopidine’s use [6].
Ticlopidine also causes thrombotic thrombocytopenic
purpura (TTP) in about 0.2% of patients during this same
period; TTP is fatal in 25–50% of patients, depending on
how rapidly plasmapheresis is initiated [7].
Because of the risk of neutropenia and TTP, patients must
undergo serial complete blood counts every 2 weeks
during the first several months of treatment with ticlopi-
dine, which is expensive and inconvenient to patients. It
has also been recommended that these serial tests con-
tinue for at least 2 weeks after discontinuation of ticlopi-
dine, because TTP can develop weeks after ticlopidine
has been discontinued [7]. Interventional cardiologists
were also eager to substitute clopidogrel for ticlopidine
owing to ticlopidine’s frequent ‘minor’ side effects, such
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as nausea, vomiting, and diarrhea, which require discontin-
uation of ticlopidine in as many as 20% of patients [8].
Clopidogrel
Clopidogrel has far fewer side effects. In randomized trials
involving roughly 50,000 patients treated with clopidogrel,
clopidogrel did not cause TTP. Subsequently, 11 cases of
TTP have been identified in the more than 3 million
patients who have taken clopidogrel in post-marketing sur-
veillance, although it is unclear whether clopidogrel actu-
ally caused the TTP in all of these cases [9]. In the only
report of clopidogrel-induced TTP by Bennett et al sum-
marizing these cases, several patients were reported to
have developed TTP while on other drugs that cause TTP
far more commonly than clopidogrel (for example,
cyclosporine). Other patients included in that report devel-
oped recurrences of TTP without re-exposure to clopido-
grel, which has never been reported for any other drug
that induces TTP. However, even if all 11 cases in that
report did develop TTP due to clopidogrel, the frequency
of clopidogrel-induced TTP would still be only 11 in about
3,000,000 patients treated. Coincidentally, this is the
same as the background frequency of TTP reported in the
general population of 3.7 per million patients [10], and
approximately 100 times less frequent than the frequency
with which ticlopidine causes TTP [7].
Clopidogrel and neutropenia
The frequency of neutropenia in patients treated with
clopidogrel is less than the 1% seen in patients treated
with ticlopidine. In the Clopidogrel versus Aspirin in
Patients at Risk of Ischaemic Events (CAPRIE) trial, the
frequency of neutropenia in patients taking clopidogrel
was the same as the background frequency in patients
taking aspirin, and was never life threatening, as it often is
when caused by ticlopidine. Therefore, serial blood counts
are not required when initiating clopidogrel [11]. In addi-
tion, clopidogrel is well tolerated. Among the 19,185
patients with vascular disease believed to be tolerant of
aspirin who enrolled in the CAPRIE trial and were random-
ized to receive either aspirin or clopidogrel, side effects
actually tended to be more common in patients treated
with aspirin than those treated with clopidogrel; only skin
rash occurred more frequently in patients treated with
clopidogrel than aspirin [11].
Onset of action
The rapidity of onset of action also favors clopidogrel in
place of ticlopidine. Five days are required for ticlopidine
to exert its full antiplatelet effect; because most patients
undergo stent placement immediately after diagnostic
angiography, they usually do not have an opportunity to be
pretreated with ticlopidine [6]. The administration of a
500 mg loading dose of ticlopidine is generally well toler-
ated and slightly reduces the time of achieving the peak
antiplatelet activity of ticlopidine; however, larger loading
doses, which achieve platelet inhibition more rapidly,
cause nausea and vomiting and cannot be used. Because
of ticlopidine’s slow onset of action, the administration of
ticlopidine and aspirin together is no more effective than
coumadin and aspirin in the first 24 h after stent place-
ment (when pretreatment with ticlopidine is not per-
formed) [5,12,13]; unfortunately, this is the time interval
during which stent thrombosis is most likely to occur
[3,4,14].
In contrast, however, large loading doses of clopidogrel
are very well tolerated, and a 375 mg dose reduces the
time to achieve peak platelet inhibition of aggregation to
6 h [15–17]. Several studies suggest that the more rapid
onset of action of clopidogrel might reduce not only the
frequency of stent thrombosis in the days after stent
placement, but also the frequency of procedural myocar-
dial infarction [12,14,18,19]. Clopidogrel is also about
30% less expensive than ticlopidine in the United States,
and results in a greater saving in many European coun-
tries. Finally, clopidogrel requires administration once
daily, whereas ticlopidine requires dosing twice daily.
Despite these advantages, the most important question
remains whether clopidogrel is as effective as ticlopidine
at preventing stent thrombosis. When clopidogrel was first
approved for use in the United States, only indirect data
suggested that it was likely to be at least as effective as
ticlopidine during coronary stent placement. The indirect
data included animal studies revealing that clopidogrel,
like ticlopidine, inhibits platelet aggregation and stent
thrombosis more effectively than aspirin, and works syner-
gistically with aspirin [20,21]. The degree of inhibition of
platelet aggregation in humans by clopidogrel is equiva-
lent to that seen with ticlopidine [22]. In addition, clopido-
grel reduces the risk of vascular death, myocardial
infarction and stroke in vascular disease patients 10%
more than aspirin does, as does ticlopidine [23,24].
On the basis of these data, many interventional cardiolo-
gists changed from administering ticlopidine to clopido-
grel after stent placement, even before randomized trials
comparing the two agents had been performed. However,
a recent report by Dr Taniuchi and colleagues of a single-
center study from Barnes Hospital in St Louis brings to
three the number of randomized trials in which patients
undergoing coronary stent placement were randomized to
receive either ticlopidine or clopidogrel (Fig. 1) [16,25,26].
The TOPPS trial
In the Ticlid or Plavix Post-Stents (TOPPS) trial, 1016
patients undergoing successful coronary stent placement
were randomized to receive aspirin and either ticlopidine
with a 500 mg loading dose followed by 250 mg twice
daily for 14 days, or clopidogrel with a 300 mg loading









received their first dose of thienopyridine within 1 h after
the procedure. This trial design more closely resembled
the practice patterns and drug regimens used in most
catheterization laboratories than those of the two previous
randomized trials comparing ticlopidine and clopidogrel.
In the first such trial, the Clopidogrel Aspirin Stent Interna-
tional Cooperative Study (CLASSICS) trial, no loading
dose of ticlopidine was administered, biasing the study
against the ticlopidine regimen. However, ticlopidine and
clopidogrel were first administered 1–6 h after stent
placement, biasing the study against the more rapidly
acting regimen, clopidogrel with a loading dose.
In the second randomized trial comparing ticlopidine and
clopidogrel, which was performed in Germany by Müller
and colleagues, no loading dose of clopidogrel was used,
as is generally done in catheterization laboratories in
which clopidogrel is used [26]. Although regimens with
loading doses have not been proved to be more effica-
cious than those without loading doses and are currently
being studied in the Clopidogrel for Reduction of Events
During Extended Observation (CREDO) trial (see below),
they clearly lead to a more rapid inhibition of platelet func-
tion, which is believed to be beneficial.
The 30-day results of TOPPS (Fig. 1) reveal that the fre-
quency of stent thrombosis, the endpoint most likely to be
influenced by the choice of thienopyridine, was 1.53% in
patients treated with ticlopidine compared with 2.02% in
the clopidogrel patients (P = 0.901). (These data differ
slightly from those in the published abstract, primarily
because of inclusion of several patients who had not yet
completed their follow-up at the time of publication of the
abstract (Dr Taniuchi, personal communication, 25 July
2000).) The frequency of cardiac death was 1.35% in
ticlopidine patients compared with 0.61% in clopidogrel
patients (P = 0.149). The cumulative frequency of major
adverse events, including cardiac death, Q-wave myocar-
dial infarction, stent thrombosis, and need for target vessel
revascularization within 30 days was 4.60% in the ticlopi-
dine cohort compared with 3.85% in the clopidogrel
cohort (P = 0.551). In contrast with several other trials, the
2-week regimen of ticlopidine was relatively well tolerated;
only 3.64% of patients treated with ticlopidine were
unable to tolerate the drug. However, side effects were
less frequent in clopidogrel-treated patients: only 1.62%
of clopidogrel patients were unable to tolerate clopidogrel.
Statistical considerations
All three of the randomized trials comparing clopidogrel
and ticlopidine in coronary stent patients were undersized
to detect a difference in the frequency of stent thrombosis.
If the true stent thrombosis rate in patients treated with
ticlopidine were 1.53%, as in TOPPS, 7596 patients in
each group would need to be enrolled to detect with 80%
power (assuming statistical significance at a P value of
0.05), a 33% reduction in the frequency of stent thrombo-
sis with clopidogrel; it is highly unlikely such a trial will ever
be conducted. Nevertheless, stent thrombosis has tended
to be similar and infrequent in both the ticlopidine and
clopidogrel treatment arms of all three trials (Fig. 2). The
small difference in the frequency of stent thrombosis
between the clopidogrel and ticlopidine arms of some of
the trials have raised concerns by some, but these have
been small and far from statistically significant; it should
be recognized that the difference in the frequency of major
adverse events between the arms of the CLASSICS trial,
for example, differ from one another by a single case of
stent thrombosis.
Other studies
In addition to TOPPS and the other two randomized trials,
seven registry experiences have been reported that com-
pared ticlopidine and clopidogrel in stent patients (Fig. 3)
[27–32] (Berger P, presented at the Transcatheter Thera-
peutics Conference, Washington DC, October 1999;
Mehran R, Dangas G, presented at the Transcatheter
Therapeutics Conference, Washington DC, October
1999). Although all of these registries are limited in one
way or another, the frequency of stent thrombosis has
tended to be infrequent in both the ticlopidine and clopi-
dogrel cohorts.
Conclusions
On the basis now of TOPPS, the two previously reported
randomized trials, and the seven registries comparing
clopidogrel with ticlopidine after stent placement, several
conclusions can be reached. Clopidogrel is better toler-
ated than ticlopidine, with far fewer life-threatening side
effects (TTP and neutropenia) and minor side effects as
Figure 1
Results of the Ticlid or Plavix Post-Stents (TOPPS) Trial. 
MI, myocardial infarction; TVR, target vessel revascularization.
well. In addition, the frequency of stent thrombosis when
clopidogrel is administered is very low. Whether the fre-
quency of stent thrombosis is as low as, or even lower
than, when ticlopidine is administered has not yet been
proved beyond a doubt.
However, on the basis of the randomized and registry data
and indirect data summarized above, it seems that clopi-
dogrel is at least as efficacious as ticlopidine at preventing
stent thrombosis and other adverse ischemic events, and
has fewer side effects. If appropriately sized randomized
trials were to be performed in the future that found a slight
difference in the frequency of stent thrombosis favoring
ticlopidine, the difference would undoubtedly be less than
the more than 1% frequency of life-threatening neutrope-
nia and TTP seen with ticlopidine administration. There-
fore, when considering the risk:benefit ratio of switching
from ticlopidine to clopidogrel after stent placement, the
driving force is clearly that there is less risk with clopido-
grel, rather than a greater benefit with clopidogrel.
Whether clopidogrel does provide greater benefit than
ticlopidine remains to be proved.
Unanswered questions
Despite TOPPS, several important questions remain unan-
swered about the use of clopidogrel after stent placement.
There are data to suggest that larger doses of clopidogrel,
up to 600 mg, act more rapidly than lower loading doses,
and are well tolerated [33]. Whether the more rapid
achievement of platelet inhibition achieved by such large
loading doses will improve clinical outcome is unknown.
However, whether large loading doses of clopidogrel are
required when a platelet glycoprotein IIb/IIIa inhibitor is
used is unknown. Peak inhibition of platelet aggregation
with even a 300 mg loading dose will still be reached
during the infusion of such agents. Platelet glycoprotein
IIb/IIIa inhibitors produce much greater inhibition of
platelet aggregation than does clopidogrel; clopidogrel
might not provide further inhibition of aggregation until the
IIb/IIIa inhibitor wears off.
Another unanswered question is the most appropriate
duration of clopidogrel after stent placement. Although
stent endothelialization is not complete for 2 months or
more, stent thrombosis occurs predominantly in the first
2 weeks after stent placement [4,5,34]. Whether a longer
duration of clopidogrel will result in an improved outcome
either by reducing late stent thrombosis or by reducing
ischemic events unrelated to the treatment site is being
also examined in the CREDO trial. In CREDO, 2000
patients undergoing percutaneous revascularization with a
coronary stent or other technique will be randomized to
receive aspirin indefinitely and either clopidogrel with a
300 mg loading dose followed 75 mg/day for 1 year, or
clopidogrel 75 mg/day for 1 month followed by placebo
for 11 months.
Summary
The TOPPS study by Taniuchi et al [25] is in agreement
with the results of other studies, indicating that the use of
clopidogrel after stent placement is associated with an
excellent clinical outcome. This and other studies support
the substitution of ticlopidine for clopidogrel that has
already occurred around the world.
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Figure 3
Data from seven registries in which the clinical outcome of patients
receiving coronary stents treated with clopidogrel was compared with
that of patients treated with ticlopidine. NS, not significant; MACE,
major adverse cardiac events.
Figure 2
The three trials in which patients receiving coronary stents were
randomized to receive one or another dosing regimen of ticlopidine or
clopidogrel. NS, not significant; MACE, major adverse cardiac events.
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